Registry for CML patients in deep remission after stopping pills
Part of Blood & lymphatic, Cancer clinical trials.
This study keeps records of people with chronic-phase CML who stopped their targeted leukemia pills (TKIs) while in a very deep remission. Researchers want to understand outcomes after stopping treatment and how often remissions are maintained.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic-phase CML (not accelerated or blastic phase)
- You took a TKI medicine, either alone or with other treatments
- You have stopped your TKI pills (for any reason)
- Before stopping, you had a very deep remission (very low BCR-ABL1 levels) confirmed multiple times
- You can and are willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stopping TKI treatment (a type of targeted therapy for CML) to see if you can stay in remission without medication. It is for people with CML in chronic phase who are either newly diagnosed or on a TKI but not achieving optimal results or not tolerating the drug.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This study looks at whether people with chronic myeloid leukemia (CML) can safely lower their dose of targeted therapy before completely stopping it. It aims to see if a gradual reduction helps maintain long-term remission without the cancer coming back.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.